Hyperliquid Strategies Inc

424B3 priced

160,000,000 shares

Hyperliquid Strategies Inc's current 424B3 filing supplements its December 2, 2025 prospectus with updated financial information from its Q4 2025 10-Q filing. The filing highlights significant net losses, unrealized digital asset losses, and ongoing operational challenges. It reaffirms the company's commitment to the Committed Equity Financing facility with Chardan Capital Markets LLC, while emphasizing the high-risk nature of investing in its common stock.

424B3 priced

160,000,000 shares

Hyperliquid Strategies Inc's 424B3 filing details a registered offering of up to 160 million shares of common stock by Chardan Capital Markets LLC under a committed equity facility. The filing follows the completion of a business combination with Sonnet BioTherapeutics, resulting in the company's Nasdaq listing under 'PURR'. The company intends to use proceeds for general corporate purposes, including potential HYPE Token purchases, while highlighting risks related to market volatility, liquidity, and dependence on the business combination.

CERT inactive

Hyperliquid Strategies Inc filed a CERT form on 2025-12-02, succeeding a previous 425 filing. The current filing likely relates to an IPO or securities offering, though specific details are obscured in the provided text. The previous 425 filing was associated with Sonnet BioTherapeutics Holdings, Inc., suggesting a potential discrepancy or error in the document metadata.

8-A12B effective

Hyperliquid Strategies Inc is registering its common stock, par value $0.0001 per share, on The Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. The registration references the company's previously filed Registration Statement on Form S-4 (File No. 333-290034), incorporating by reference the description of its capital stock from the prospectus. No exhibits are required as the securities are not registered under Section 12(g).

425 supplemental

Hyperliquid Strategies Inc. is involved in a business combination with Sonnet BioTherapeutics Holdings, Inc., which requires shareholder approval. The special meeting to vote on the transaction was adjourned to allow more time for shareholder voting, with over 95% of voted shares currently in favor. The transaction remains pending regulatory and shareholder approvals, and Hyperliquid's shares are approved for Nasdaq listing.

425 supplemental

Hyperliquid Strategies Inc. filed a Form 425 related to Sonnet BioTherapeutics Holdings, Inc.'s adjournment of its special meeting to extend voting time for a proposed business combination. The meeting was adjourned to secure majority shareholder approval, with over 95% of votes cast in favor of the transaction. HSI's shares are approved for Nasdaq listing, and the rescheduled meeting is set for December 2, 2025.

425 supplemental

Hyperliquid Strategies Inc. (Pubco) is undergoing a business combination with Sonnet BioTherapeutics Holdings, Inc., involving a merger structure where Sonnet's shareholders will receive Pubco shares and contingent value rights (CVRs). The transaction requires stockholder approval, with shares of Pubco Common Stock expected to be listed on Nasdaq under 'PURR'. The merger includes complex share conversions, vesting terms for restricted stock units, and warrant adjustments.

424B3 priced

154,766,330 shares

Hyperliquid Strategies Inc. (HSI) is involved in a business combination with Sonnet BioTherapeutics Holdings, Inc., involving a merger structure where Sonnet's shares will convert into HSI stock and contingent value rights (CVRs). The filing outlines shareholder votes required for the transaction, including approval of the merger agreement, organizational documents, and other proposals. HSI plans to list on Nasdaq under 'PURR' and details the share issuance and warrant structures.

S-1 filed

Hyperliquid Strategies Inc (formerly Sonnet BioTherapeutics Holdings Inc) filed an S-1 registration statement for an IPO, following an earlier S-4/A filing. The current filing includes updated financial data through 2025-06-30, new subsequent events, and expanded details on stock warrants, retained earnings, and corporate structures. The company appears to be preparing for a public offering, with disclosures covering multiple subsidiaries and complex capital structure elements.

S-4/A amended

The current S-4/A filing for Hyperliquid Strategies Inc appears to include updated financial data and transaction-related disclosures, though the text primarily consists of repetitive financial statement line items and accounting metadata. The filing references entities like Sonnet BioTherapeutics Holdings Inc and Rorschachi LLC, but no explicit business updates or strategic changes are detailed.

S-4/A amended

Hyperliquid Strategies Inc's S-4/A filing reflects an amendment to its previous S-4 registration statement, primarily focusing on updated financial data and corporate structure details. The filing includes extensive disclosures related to stockholder equity, retained earnings, and various contractual agreements, but no explicit details on the IPO offering itself. The document references entities like SonnetBioTherapeuticsHoldingsInc and RorschachiLlc, though the connection to Hyperliquid Strategies Inc remains unclear.

S-4 filed

Hyperliquid Strategies Inc (HSI) is registering securities for a business combination involving a merger with Rorschach I LLC. The transaction involves two mergers: Rorschach Merger Sub merging into Rorschach, and Company Merger Sub merging into Sonnet BioTherapeutics Holdings, Inc. Shareholders of Sonnet will receive Pubco Common Stock and contingent value rights (CVRs). The merger is expected to result in HSI's stock being listed on the Nasdaq Capital Market under the symbol HYPL.

DRS filed

Hyperliquid Strategies Inc. filed a confidential Form S-4 registration statement dated August 1, 2025, related to a business combination involving a merger with Rorschach I LLC. The filing outlines the proposed merger structure, shareholder voting requirements, and details about the conversion of Sonnet BioTherapeutics Holdings, Inc. securities into Hyperliquid Strategies Inc. shares. The transaction requires shareholder approvals for multiple proposals, including the business combination, organizational document changes, and Nasdaq listing compliance. The company plans to list on Nasdaq under the symbol HYPL post-merger.